BRAF and glioblastoma: In our analysis, around 10.0% of the Lebanese GBM patients had BRAF mutations (95% CI: 2.4–17.6), with missense mutations of the V600E type accounting for 3.3% of the samples (95% CI: -1.2–7.9; n = 2/60).